Status: Recruiting
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
Participants needed: 64
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Capstan TherapeuticsUpdated: Jul 16, 2026Locations: 3
Eligibility criteria
Male and female participants who are healthy as determined by the investigator b... [+6]
Evidence of organ dysfunction or any clinically significant deviation from norma... [+3]